Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical Research

Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis

Prostate Cancer and Prostatic Diseases volume 20, pages 352–360 (2017)Cite this article

Subjects

Abstract

Background:

Promising therapeutic results of the prostate-specific membrane antigen (PSMA) ligand have been shown when labelling with lutetium-177 (177Lu). We performed a systematic review and meta-analysis to assess the therapeutic response of 177Lu-PSMA in the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Methods:

A systematic review was conducted using electronic databases up to December 2016. Two reviewers independently extracted data and assessed methodological quality. The main outcome of interest was antitumour biochemical response of 177Lu-PSMA, analysing two measures: ‘any PSA decline’ and ‘>50% decline’ from baseline. A random-effects meta-analysis was used to calculate the pooled proportion across studies. The I2 statistic was calculated in each case to investigate the extent of heterogeneity across the studies. A sensitivity analysis was conducted removing two studies, which were presented as abstracts and proportions were summarised by chemical type (177Lu-J591/DKZ/I&T). All analyses were conducted using Stata v14.

Results:

A total of 10 studies were included in the analysis giving a total sample size of 369, 220 (of 334 analysable) experienced any PSA decline. The pooled proportion of patients with any PSA decline was 68% (95% confidence interval (CI): 61–74). The I2 statistic was 39.1% (P=0.11) suggesting minor heterogeneity between results. The pooled proportion of patients with >50% PSA decline was 37% (95% CI: 22–52). The I2 statistic was 91.0% (P<0.001) suggesting substantial heterogeneity between results. On subgroup analysis, a higher proportion of patients in the 177Lu-DKZ/I&T subgroup had a PSA decline >50%, however, it can be seen that the 177Lu-DKZ/I&T subgroup had a substantial amount of heterogeneity across studies.

Conclusions:

This review suggests promising early results for the treatment of mCRPC, especially from patients treated with the more recently developed radioligands. Overall, our meta-analysis showed that approximately two-thirds of patients had a biochemical response. Randomised-controlled trials would be necessary to verify its effectiveness against current systemic therapies and create an ideal treatment protocol.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Conford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic and castration-resistant prostate cancer. Eur Urol 2017; 71: 630–642.

    Article  Google Scholar 

  2. Kulkarni HR, Singh A, Schuchardt C, Niepsch K, Sayeg M, Leshch Y et al. PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the bad berka experience 2013. J Nucl Med 2016; 57: 97S–104S.

    Article  CAS  PubMed  Google Scholar 

  3. Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S et al. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med 2016; 57: 1006–1013.

    Article  CAS  PubMed  Google Scholar 

  4. Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 1998; 58: 4055–4060.

    CAS  PubMed  Google Scholar 

  5. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumour vascular endothelium. Cancer Res 1997; 57: 3629–3634.

    CAS  PubMed  Google Scholar 

  6. Vallabhajosula S, Nikolopoulou A, Jhanwar YS, Kaur G, Tagawa ST, Nanus DM et al. Radioimmunotherapy of metastatic prostate cancer with 177Lu-DOTA-huJ591 anti-prostate specific membrane antigen specific monoclonal antibody. Curr Radiopharm 2016; 9: 44–53.

    Article  CAS  PubMed  Google Scholar 

  7. Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003; 170: 1717–1721.

    Article  CAS  PubMed  Google Scholar 

  8. Kularatne SA, Zhou Z, Yang J, Post CB, Low PS . Design, synthesis, and pre-clinical evaluation of prostate specific membrane antigen targeted 99mTc-radioimmaging agents. Mol Pharm 2009; 6: 790–800.

    Article  CAS  PubMed  Google Scholar 

  9. Zhang AX, Murelli RP, Barinka C, Michel J, Cocleaza A, Jorgensen WL et al. A remote arene-bidning site on prostate specific membrane antigen revealed by antibody-recruiting small molecules. J Am Chem Soc 2010; 132: 12711–12716.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S et al. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA targeted theranostic concept and first proof of concept human studies. J Nucl Med 2015; 56: 1169–1176.

    Article  CAS  PubMed  Google Scholar 

  11. Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N et al. Pre-clinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res 2009; 69: 6932–6940.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Benesova M, Schafer M, Bauder-Wust U, Afshar-Oromieh A, Kratochwil C, Mier W et al. Preclinical evaluation of tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med 2015; 56: 914–920.

    Article  CAS  PubMed  Google Scholar 

  13. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ . Phase I trial of 177lutetium labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostatecancer. J Clin Oncol 2005; 23: 4591–4601.

    Article  CAS  PubMed  Google Scholar 

  14. Tagawa ST, Milowsky M, Morris M, Vallabhajosula S, Christos P, Akhtar NH et al. Phase II study of Lutetium-177-labelled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res 2013; 46: 220–231.

    Google Scholar 

  15. Ahmadzadehfar H, Rahbar K, Kurpig S, Bogemann M, Claesener M, Eppard E et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res 2015; 5: 1–8.

    Article  Google Scholar 

  16. Heck MM, Retz M, D’Alessandria C, Rauscher I, Scheidhauer K, Maurer T et al. Systemic radioligand therapy with 177Lu labeled prostate specific membrane for imaging and therapy in patients with metastatic castration-resistant prostatecancer. J Urol 2016; 196: 382–391.

    Article  CAS  PubMed  Google Scholar 

  17. Fendler WP, Reinhardt S, Ilhan H, Delker A, Boning G, Gildehaus FJ et al. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget 2016; 8: 3581–3590.

    PubMed Central  Google Scholar 

  18. Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med 2017; 58: 85–90.

    Article  CAS  PubMed  Google Scholar 

  19. Tagawa ST, Batra J, Vallabhajosula S, Jhanwar Y, Christos PJ, Emmerich L et al Final results of 2-dose fractionation of 177Lu-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC). Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO. J Clin Oncol 2016; 34 (abstract 5022).

    Article  Google Scholar 

  20. Rathore H, Shah H, Aland P, Chaudhuri P, Bharadwaj T, Kale C et al. Assessment of response, clinical evaluation and toxicity of radioligand therapy (RLT) with 177-Lutetium-DKFZ-617-labeled prostate specific membrane antigen (177-Lu-DKFZ-617-PSMA) for metastatic castrate resistant prostate cancer (mCRPC): an initial experience in Jaslok. Conference: 29th Annual Congress of the European Association of Nuclear Medicine, EANM 2016, Spain. Eur J Nucl Med Mol Imaging 2016; 43: S414.

    Article  Google Scholar 

  21. Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A et al. 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment. Eur J Nucl Med Mol Imaging 2017; 44: 81–91.

    Article  CAS  PubMed  Google Scholar 

  22. Kirby M, Hirst C, Crawford ED . Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011; 65: 1180–1192.

    Article  CAS  PubMed  Google Scholar 

  23. Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care, Ontario clinical practice guideline. J Clin Oncol 2014; 32: 3436–3448.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995–2005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187–1197.

    Article  CAS  PubMed  Google Scholar 

  26. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61: 1079–1092.

    Article  PubMed  Google Scholar 

  27. Kiess A, Minn I, Chen Y, Hobbs R, Sgouros G, Mease RC et al. Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen. J Nucl Med 2015; 56: 1401–1407.

    Article  CAS  PubMed  Google Scholar 

  28. Tagawa ST, Akhtar NH, Nikolopoulou A, Vallabhajosula S, Osborne J, Beltran H et al. Phase I trial of fractionated-dose 177Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer (CRPC). Conference: European Cancer Congress, ECC 2013, Amsterdam, Netherlands. Eur J Cancer 2013; 49: S701–S702.

    Google Scholar 

  29. Tagawa ST, Whang YE, Kaur G, Vallabhajosula S, Christos PJ, Nikolopoulou A et al. Phase I trial of docetaxel/prednisone plus fractionated dose radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody 177Lu-J591 in patients with metastatic, castration-resistant prostate cancer (mCRPC). Conference: Annual Meeting of the American Society of Clinical Oncology, ASCO, Chicago, United States, 2014. J Clin Oncol 2014; 32 (Suppl 1): 15.

    Google Scholar 

  30. Lutje S, Heskamp S, Cornelissen AS, Poeppel TD, van den Broek SA, Rosenbaum-Krumme S et al. PSMA ligands for radionuclide imaging and therapy of prostate cancer: clinical status. Theranostics 2015; 5: 1388–1401.

    Article  PubMed  PubMed Central  Google Scholar 

  31. De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147–1154.

    Article  CAS  PubMed  Google Scholar 

  32. Scher HI, Morris MJ, Basch E, Heller G . End points and outcomes in castration resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol 2011; 29: 3695–3704.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Evans-Axelsson S, Timmermand O, Bjartell A, Strand SE, Elgqvist J . Radioimmunotherapy for prostate cancer: current status and future possibilities. Semin Nucl Med 2016; 46: 165–179.

    Article  PubMed  Google Scholar 

  34. Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996; 48: 326–334.

    Article  PubMed  Google Scholar 

  35. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010; 11: 1066–1073.

    Article  CAS  PubMed  Google Scholar 

  36. Spratt DE, Evans MJ, Davis BJ, Doran MG, Lee MX, Shah N et al. Androgen receptor upregulation mediates radioresistance after ionizing radiation. Cancer Res 2015; 75: 4688–4696.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Tosoian JJ, Gorin MA, Rowe SP, Andreas D, Szabo Z, Pienta KJ et al. Correlation of PSMA-targeted 18F-DCFPyL PET/CT findings with immunohistochemical and genomic data in a patient with metastatic neuroendocrine prostate cancer. Clin Genitourin Cancer 2017; 15: e65–e68.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Uro-Oncology, Chris O’Brien Lifehouse, University of Sydney, Sydney, NSW, Australia

    R J S Calopedos, R Asher & H H Woo

  2. Northern Clinical School, University of Sydney, Sydney, NSW, Australia

    V Chalasani & H H Woo

  3. NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia

    R Asher

  4. Nuclear Medicine Department, St Vincent’s Hospital, Sydney, NSW, Australia

    L Emmett

Authors
  1. R J S Calopedos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V Chalasani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Asher
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Emmett
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H H Woo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H H Woo.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Prostate Cancer and Prostatic Diseases website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Calopedos, R., Chalasani, V., Asher, R. et al. Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 20, 352–360 (2017). https://doi.org/10.1038/pcan.2017.23

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2017.23

This article is cited by

Search

Advanced search

Quick links